Compare FCEL & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCEL | OBX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.3M | 848.8M |
| IPO Year | 2005 | 2026 |
| Metric | FCEL | OBX |
|---|---|---|
| Price | $6.62 | $11.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $21.10 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 4.9M | 541.6K |
| Earning Date | 12-17-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.71 | $9.60 |
| 52 Week High | $37.88 | $39.00 |
| Indicator | FCEL | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 28.21 | 41.92 |
| Support Level | $6.18 | $11.84 |
| Resistance Level | $7.31 | $15.87 |
| Average True Range (ATR) | 0.93 | 1.60 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 1.58 | 42.68 |
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.